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Influenza constitutes an annually recurring threat to society, from 
both the clinical and economic points of view. The impact of influ-
enza is often underestimated, especially among frail elderly peo-
ple, who are at increased risk of serious complications, including 
hospitalization and death. In Italy, around 10 million individuals 
aged 65 years and older are at risk of contracting influenza, and 
it can be estimated that the lack of a vaccination strategy would 
lead to more than 2 million cases and about 30,000 deaths. How-
ever, adherence to routinely recommended adult immunizations 
remains suboptimal despite the availability of safe and effective 
vaccines. Indeed, a monitoring program from the National Insti-
tute of Health in Italy has shown that influenza vaccination cov-
erage in the elderly dropped to 49% in the 2014-2015 season, 
which is far below the maximum values (68%) recorded in the 
2005-2006 season. The current situation in Italy imposes a need 
for greater sustainability in order to face the challenges related to 
the changing epidemiological situation, demographic transition 
and social transformations. Our review sums up the key elements 
of influenza vaccine sustainability and makes suggestions for 
improving the organizational structure of the present initiatives. 
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Summary
Introduction
Influenza is considered a highly contagious respiratory 
illness, mainly because unstable viruses periodically 
drift and shift their antigens from one season to another 
to evade the immune system.
Annual winter outbreaks of influenza are a major cause 
of morbidity and mortality, especially among frail elder-
ly people, who are at increased risk of serious complica-
tions, including hospitalization and death [1]. 
Although the public perception in many countries is that 
seasonal influenza is a mild illness, with a low to negli-
gible impact on health and economies, annual influenza 
attack rates range from 5-10% in adults to 20-30% in 
children, generating high healthcare costs and placing a 
significant clinical and economic burden on patients and 
society [2].
Worldwide, these annual epidemics are estimated to re-
sult in about 3 to 5 million cases of severe illness, and 
about 250,000 to 500,000 deaths  [3]. From 1976 to 
2007, individuals aged ≥ 65 years accounted for approxi-
mately 90% of all influenza-related deaths in the USA. 
Furthermore, during the period 1999-2010, it was esti-
mated in the UK that 2.5-8.1% of deaths among those 
aged ≥ 75 years were due to influenza [4]. 
Founded in 1999, Influnet is an Italian network of sen-
tinel physicians, it aims to monitor seasonal trends in 
influenza-like syndromes (influenza-like illness, ILI) in 
the population. According to the estimates made from 
the data gathered, ILI affects 4-12% of the population 
each year, with an average of 7.5% recorded in the pe-
riod 2011-2014 [5]. 
The clinical impact of seasonal influenza epidemics in 
Europe has recently been extrapolated from American 
data. According to these estimates, in Italy about 6,000 
deaths and 38,000 excess hospitalizations are attribut-
able to influenza [6].
The economic impact of influenza primarily involves 
healthcare resource utilization by elderly and high-risk 
groups and work absenteeism among otherwise healthy 
working adults [7]. In 2013, the costs attributable to the 
four main adult Vaccine-Preventable Diseases (VPD) in 
the United States were estimated to be around $ 26 bil-
lion, with influenza accounting for the majority of cases 
of adult VPD (81% of adults aged 50 and older and 77% 
of adults aged 65 and older). Moreover, the highest an-
nual costs (medical and indirect costs) were indeed re-
lated to influenza. Influenza accounted for $ 16,0 billion 
(60%) of the cost among adults older than 50 years and 
$ 8,3 billion (54%) among those aged 65 and older [8].
From the patient perspective, an average episode of ILI 
and clinically diagnosed influenza in the out-of-hospital 
Belgian general population costs € 51-53 in direct medi-
cal costs, 4 days of absence from work or school and the 
loss of 0.005 quality-adjusted life-years [9]. In Italy, the 
average length of absence from work or school is around 
4.8 days, and 10% of all work absences are due to influ-
enza. The total cost of each case of influenza is estimat-
ed to be about € 330 [10], with indirect costs accounting 
for a further € 364-774 (values from 2011) [11].
A. POSCIA ET AL.
E10
Considering that in Italy there are nearly 10  million 
individuals aged 65 years and older who are at risk of 
contracting influenza, it can be estimated that the lack 
of a vaccination strategy would lead to more than 2 mil-
lion cases and about 30,000 deaths. Indeed, vaccination 
has the potential to reduce the number of cases to 1,3-
1,5 million. Hence, the reduction in the number of hos-
pital admissions would eventually lead to a reduction in 
healthcare costs of up to € 80 million (specifically, after 
administration of vaccines containing adjuvants) [10]. In 
this regard, one Italian study analyzed data gathered from 
the cohort of elderly individuals in the Liguria Region; 
the authors estimated that the costs resulting from hos-
pitalization due to influenza were 5 times higher among 
non-vaccinated subjects than vaccinated subjects [12].
Moreover, vaccination targeting people from 50 to 
64  years old in Italy has the potential to avoid about 
100,000 cases of ILI (about 10% of the total), 3,000 hos-
pitalizations (60%), 232 deaths (out of a total of 989) 
and more than 110,000 days of lost work [6]. 
European and national strategies and 
sustainability of influenza vaccination
Bearing in mind the clinical, economic and social  im-
pacts of influenza, the World Health Organization has 
proposed vaccination as a cost-effective and a cost-ben-
eficial tool for preventing serious forms and complica-
tions of influenza, and reducing premature  mortality 
in groups at increased risk of serious illness.
In Italy, the 2012-2014 National Immunization Preven-
tion Plan introduced influenza vaccination for the elderly 
(65 years and over), with coverage targets of 75% (mini-
mum achievable goal) and 95% (optimal goal in the tar-
get population). The objective was to reduce individual 
risk of illness, hospitalization and death, and the related 
social costs. In addition, several countries have lowered 
the age threshold to 60 or 50 years for free-of-charge 
influenza vaccination. These decisions were based on 
pharmacoeconomic evaluations, which proved that this 
age-based approach was sustainable, cost-effective and 
also cost-saving, owing to the increased probability of 
adherence to vaccination by the population. This ap-
proach, together with the analysis published in 2012 by 
the Italian Society of Hygiene (SItI) [13], prompted the 
Italian Ministry of Health to launch a thorough discus-
sion among all stakeholders, in order to assess the pos-
sibility of progressively reducing the age threshold in the 
upcoming national anti-influenza recommendations.
Although infectious diseases in older adults have a huge 
burden, adherence to routinely recommended adult im-
munizations across Europe remains suboptimal, despite 
the availability of safe and effective vaccines [1]. Still, 
vaccination is considered the most efficacious public 
health tool currently available to protect elderly individ-
uals against influenza [4].
European data indicate that vaccination coverage in 
groups at risk (patients with concomitant disease) is 
around 35%  [10]. In Italy, monitoring carried out by 
the National Institute of Health has shown a progres-
sive decline in coverage from the maximum value (68%) 
recorded in the 2005-2006 season. The lowest levels, 
reached in the 2014-2015 influenza season, indicated 
that national coverage had dropped to 49%, another 
5 percentage points below the previous season (Fig. 1). 
This decline in coverage is affecting all Italian regions, 
with reductions ranging from a minimum value in Lom-
bardy (-3.3%) to a maximum value in Abruzzo (-28.0%), 
and is depressing Italian coverage rates to the levels es-
timated fifteen years ago. This situation is making it 
increasingly difficult for Italy to achieve the European 
target coverage  [14] and must surely prompt profound 
reflection. Indeed, it is essential to implement measures 
aimed at turning this situation around; a prerequisite to 
achieving this is understanding why vaccination, which 
has been unquestionably successful, is shunned by so 
many people.
While disaffection with vaccination can be partly at-
tributed to the growing number of anti-vaccination cam-
paigns, it stems in large part from the difficulties that the 
National Health System has in allocating the human/fi-
nancial resources needed to carry out effective informa-
tion campaigns directed towards citizens and healthcare 
workers. The problem of resource allocation is common 
to many prevention activities that involve immediate 
costs but yield medium/long-term results. Moreover, 
these results are often hardly visible, as the success of 
such initiatives lies in the non-occurrence of a negative 
event, and therefore a “non-event”. This presumably ex-
plains why the funding of prevention programs in Italy 
has traditionally been even lower than the already lim-
ited 5% established in the planning documents.
While the European Union has more than doubled its 
funds for immunization worldwide, from € 10 million 
to € 25 million  for the period 2014-2020, Italy is ex-
periencing a decrease in expenditure on vaccines and a 
series of difficulties in approving a new national preven-
tive vaccination plan [10]. Indeed, last year’s data from 
OSMED (National Observatory on Drug Use) indicated 
a 21.2% reduction in spending on influenza vaccines: 
Fig. 1. Influenza vaccination: vaccination coverage in the elderly 
(age > = 65 years) (per 100 inhabitants) Seasons 1999-2000/2014-
2015 (Source: Ministry of Health – ISS, based on the summaries 
submitted by the Regions and Autonomous Provinces of Italy).
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around € 39 million in total [15, 16]. At the same time, 
however, around 41.0% of subjects diagnosed with a 
viral infection of the upper respiratory tract (influenza, 
cold, acute laryngotracheitis) received an inappropriate 
antibiotic prescription. This exemplifies how the initial 
failure to pay for vaccine administration later impacts on 
patients in terms of increased disease risk and treatment 
costs.
Bearing in mind the need for the widespread adminis-
tration of influenza vaccine and the complexities of its 
distribution, it is obvious just how crucial it is to have a 
comprehensive communication plan and well-designed 
infrastructure in order to ensure a maximally effective 
system of influenza prevention  [17]. A clear influenza 
vaccination policy is essential and the lack of one is a 
key obstacle to influenza programs. Each country cur-
rently handles its own vaccination program/policy, and 
the lack of international coordination results in the wide 
variability of vaccine supplies and population targets, 
thereby potentially exacerbating inequalities at the in-
ternational and national levels. Furthermore, discrepan-
cies in several choices may be difficult for citizens to 
understand and could facilitate the activities of the anti-
vaccination movements.
Communication supports the development and imple-
mentation of these policies and transforms them into a 
language that will resonate with policy-makers, partners 
and the public. A recent study on vaccine programs for 
European citizens aged 60 years and older showed that, 
in addition to improved access to vaccines, communica-
tion and the awareness of vaccine-preventable diseases, 
as promoted through an efficient system of reminders, 
recalls and information, are the main parameters lead-
ing to success in establishing a vaccine program  [18]. 
Strategies targeted at increasing positive attitudes, such 
as health education by means of educational videos, may 
enhance vaccine acceptance and improve knowledge 
and attitudes in the elderly [19].
Strengthening the communication capacities of the vari-
ous contributors to influenza programs should ensure 
that all stakeholders, especially the public and the me-
dia, have access to available resources, tools and scien-
tific expertise. Also, promoting communication between 
scientists and practitioners should create a suitable en-
vironment for transparent information sharing with all 
the stakeholders. Moreover, communication needs to be 
adapted to the various local and cultural situations (lan-
guage, content of information, and means of communi-
cation). Not only should communication be go beyond 
pure messaging and providing information; monitoring 
and evaluation of the communication process is also 
critical. Various tools could be used for these purposes, 
such as social network analysis, surveys, interviews etc., 
and the results should be used to adjust decision-making 
processes at the political, programmatic and technical 
levels.
Reaching out to the subjects that need to be involved 
is generally not enough to gain public support for pre-
vention programs. The training of health workers, who 
ought to be motivated and committed to the individual 
and collective interests of vaccinations, is essential. In-
deed, non-adherence to vaccination often stems more 
from the lack of motivation of educational trainers than 
from opposition on the part of families. The key role of 
healthcare workers in promoting access to and aware-
ness and acceptance of, influenza vaccination should 
not be taken for granted, and strengthening the role of 
healthcare providers is of the highest importance. At the 
same time, it is very important that people living with or 
caring for aging adults get vaccinated. Healthcare per-
sonnel are in regular contact with at-risk populations, 
and strategies for improving vaccination rates among 
health employees are absolutely essential [20].
Vaccine services should have an efficient organizational 
structure in order to satisfy the needs of the population 
and ensure the success of vaccination programs. In this 
regard, the evaluation of vaccination coverage enables 
identification of the areas where infectious diseases may 
occur more easily. Therefore, the influenza vaccination 
coverage is a key indicator for assessing the effective-
ness of vaccine supply, especially in such target popula-
tion groups as the elderly.
Implementing a computerized system of vaccine regis-
tries (computerized immunization registries) connected 
with municipal registry offices should be seen as a pre-
requisite to increasing the quality of immunization ser-
vices, and should be integrated with other existing data-
bases, such as those of sentinel sites, population-based 
studies, hospitals and out-patient clinics and regional 
authorities. Indeed, the absence of an accurate surveil-
lance system is considered one of the main obstacles to 
establishing evidence-based policies to reduce the im-
pact of influenza nationally.
Conclusions
Influenza constitutes a serious health threat, especially 
for vulnerable populations such as older adults. The 
importance of promoting healthy aging and increasing 
vaccination coverage, by sustaining a life-course im-
munisation approach to limit the burden of the disease, 
is evident. The current economic and socio-political 
climate, which is characterized by scant resources and 
cost-cutting, imposes on our healthcare system the need 
for a new model of sustainability – one which would be 
able to face the new challenges related to the changing 
epidemiological situation, demographic transition and 
great social transformations. In this regard, financial 
difficulties could be seen as an opportunity to enhance 
vaccine prevention as part of a system that makes good 
health investments that impact positively on direct and 
indirect healthcare costs.
In addition, not only should the costs of a vaccination 
campaign be programmed; they could also be notably 
lower than the unpredictable costs of the disease that is 
to be avoided, thus confirming that investment in pre-




The need to support public health and to stress the social 
and economic value of vaccination is now greater than ev-
er. Communication and the awareness of vaccine-prevent-
able diseases in the general community is an important 
starting point, and all healthcare professionals and public 
health/social workers can play a key role in this regard.
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